MYCN and neuroblastoma: These findings establish the double-transgenic line nf1-deficient/MYCN-overexpressing zebrafish as a valuable tool for testing new therapeutic strategies for NB with mutations affecting the RAS-MAPK pathway, which appear to be a major cause of relapse in patients with NB [85].